Evidence map›Paper›PMID 42124356›Full record

Trial reportAmerican journal of hematology2026

RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.

Cong Li, Tao Lei, Xiyue Xu, Jialiang Lu, Xiu Zhu, Zhilu Chen, Xiang Weng, Haifeng Yu, Xi Chen, Shuailing Peng and 2 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cong LiDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0001-5976-7562
Tao LeiDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0006-3920-5785
Xiyue XuDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0004-2526-0797
Jialiang LuDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0003-3514-981X
Xiu ZhuDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-5945-0941
Zhilu ChenDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0002-7970-108X
Xiang WengDepartment of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China.ORCID https://orcid.org/0009-0003-7370-7947
Haifeng YuDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0000-9884-9894
Xi ChenDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0002-4592-850X
Shuailing PengDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0006-1535-7338
Shuiyun HanDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-0004-2812
Haiyan YangDepartment of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-1371-3734

Funding

Key Research and Development Program of Zhejiang Province 2024C03158National Natural Science Foundation of China 82470179Zhejiang Clinovation Pride
6 · The paper itself

Abstract

Relapsed/refractory (r/r) angioimmunoblastic T-cell lymphoma (AITL) is associated with a dismal prognosis, with historical overall survival (OS) < 6 months, underscoring the urgent need for novel therapies. We conducted the RCLARITY trial to evaluate the efficacy and safety of a chemotherapy-free regimen in this patient population. This single-arm, multicenter, prospective Phase II trial enrolled adult patients with r/r AITL. Patients received rituximab (375 mg/m

Indexed as

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBenzamidesImmunoblastic LymphadenopathyLenalidomideLymphoma, T-CellRituximabAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesRecurrenceAminopyridinesBenzamidesLenalidomideN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideRituximabangioimmunoblastic T‐cell lymphomaChidamideIg rearrangementlenalidomiderituximab

Identifiers

PMID42124356
PMCPMC13544474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.